PBRT vs. IMRT — patients can now enroll at more sites

The “New” Prostate Cancer InfoLink has consistently encouraged newly diagnosed patients who are thinking about radiation therapy as treatment for low- and intermediate-risk, localized prostate cancer to consider enrolling in the ongoing, randomized, Phase III clinical trial known as the PARTIQoL trial. … READ MORE …

Using the modified poliovirus to treat prostate cancer

For the benefit of those who saw (or heard about but did not see) the “60 Minutes” program last night dealing with the use of modified poliovirus in the treatment of patients with recurrent glioblastoma (a form of brain cancer), let us be very clear. … READ MORE …

Transrectal biopsy and the increasing risk for procedure-related infection

According to a paper presented at the recent meeting of the European Association of Urology in Madrid, Spain, there seems to be a significant and ongoing rise in the global risk for infections associated with prostate biopsy (and particularly with the transrectal prostate biopsy). … READ MORE …

Use of CTCs to assess response to abiraterone acetate at 12 weeks on therapy

Back in 2011 we reported a presentation by Scher et al. indicating that circulating tumor cell counts (CTCs) could probably be used to monitor responses to abiraterone acetate (and perhaps other forms of drug therapy) in the treatment of men with metastatic, castration-resistant prostate cancer. … READ MORE …

Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

Vitamin D as a treatment for low-risk prostate cancer? Not based on these data!

A presentation at a meeting of the American Chemical Society in Denver earlier this week suggested the possibility that men who took 4,000 IU of vitamin D every day for 60 days prior to a radical prostatectomy did better than similar men taking a placebo. … READ MORE …

Will Lu-177-anti-PSMA be the next Xofigo?

Xofigo® (radium Ra-223 dichoride) has been a game-changer in the treatment of prostate cancer metastatic to bone. Not only does it provide significant pain palliation and reduce skeletal-related adverse events, but it slows down progression of the disease, increasing median survival by about 30 percent. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,254 other followers